• Earlier in 2026, Evercore ISI initiated coverage of PROCEPT BioRobotics with an “Outperform” rating, as the company reported completing enrollment in its WATER IV RP randomized prostate cancer trial and securing FDA approval for the WATER IV AS study.
• These prostate cancer milestones suggest Aquablation therapy could move beyond benign prostatic hyperplasia into a broader urologic oncology role, drawing fresh analyst attention to PROCEPT’s growth pathway.
• We’ll now examine how progress in the WATER IV prostate cancer program may reshape PROCEPT BioRobotics’ investment narrative and long-term opportunity.

Uncover the next big thing with 22 elite penny stocks that balance risk and reward.

PROCEPT BioRobotics Investment Narrative Recap

To own PROCEPT BioRobotics, you need to believe Aquablation can become a core urologic procedure across both benign prostatic hyperplasia and prostate cancer, supporting a larger installed base and rising procedure volumes over time. The key near term catalyst remains broader adoption helped by improved reimbursement, while the central risk is continued operating losses if utilization lags expectations. The new WATER IV prostate cancer milestones reinforce the long run opportunity but do not materially change that near term risk balance yet.

The most relevant update here is PROCEPT’s May 28 announcement that it completed enrollment in the WATER IV RP randomized trial and secured FDA approval for the WATER IV AS study. These studies extend Aquablation into prostate cancer, directly tying clinical progress to the longer term catalyst of expanding indications. If they ultimately support regulatory and guideline momentum, they could help offset future competitive and reimbursement pressures that currently sit at the heart of the risk case.

Yet against this promising clinical story, investors should also be aware of the ongoing risk that persistent operating losses and heavy R&D investment could...

PROCEPT BioRobotics' narrative projects $608.2 million revenue and $77.8 million earnings by 2029. This requires 23.6% yearly revenue growth and a $180.3 million earnings increase from -$102.5 million today.

Uncover how PROCEPT BioRobotics' forecasts yield a $30.44 fair value, a 35% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts take a much tougher view than consensus, even before this WATER IV news, assuming about 23.5% annual revenue growth but no profitability in the next three years, which highlights how much opinions can diverge and why it is worth comparing several viewpoints before you decide how this new prostate cancer data fits your own expectations.

Explore 8 other fair value estimates on PROCEPT BioRobotics - why the stock might be worth over 2x more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your PROCEPT BioRobotics research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free PROCEPT BioRobotics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate PROCEPT BioRobotics' overall financial health at a glance.

No Opportunity In PROCEPT BioRobotics?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.